Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
JPMorgan Chase & Co. filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 3,881,790 shares of Class A common stock of HIMS & HERS HEALTH, INC., representing 1.7% of the class as reported.
The filing lists specific voting and dispositive powers: sole power to vote 3,399,965, shared power to vote 13, sole power to dispose 3,879,553, and shared power to dispose 2,145. It identifies subsidiaries including J.P. Morgan Trust Company of Delaware and J.P. Morgan Securities LLC. The form is signed by a JPMorgan vice president on 03/05/2026.
Hims & Hers Health, Inc. Chief Legal Officer Boughton Soleil sold 4,651 shares of Class A common stock in an open-market transaction. The shares were sold at an average price of $15.21 per share. After this sale, Soleil continues to hold 440,972 shares directly. The transaction was carried out under a pre-established Rule 10b5-1 trading plan adopted on November 18, 2025, indicating it was scheduled in advance rather than decided at the time of sale.
Hims & Hers Health, Inc. reported that Chief Financial Officer Oluyemi Okupe acquired 410,690 shares of Class A common stock through earned performance-based restricted stock units. The Compensation Committee certified the performance goals on February 23, 2026, and the related shares are scheduled to be delivered around March 15, 2026.
Hims & Hers Health, Inc. reported that Chief Legal Officer Boughton Soleil acquired 273,794 shares of Class A common stock through a performance-based restricted stock unit (PRSU) award. The award carried a price of $0.00 per share and lifted Soleil’s directly held stake to 445,623 shares.
The PRSUs were earned under a previously granted award after the Compensation Committee certified that the performance criteria were met as of February 23, 2026. Under the award terms, the underlying shares are scheduled to be delivered to Soleil on or about March 15, 2026.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported acquiring 365,058 shares of Class A common stock through earned performance-based restricted stock units (PRSUs). These PRSUs were previously granted and each unit represents the right to receive one share.
The Compensation Committee certified that the award's performance criteria were met as of February 23, 2026, and the shares are scheduled to be delivered to Chi on or about March 15, 2026. Following this grant, his direct holdings total 670,219 shares of Class A common stock.
Hims & Hers Health, Inc. reported that Chief Executive Officer Andrew Dudum acquired 794,002 shares of Class A common stock through the earning of performance-based restricted stock units (PRSUs). The award carried a grant price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
These PRSUs were earned after the Compensation Committee certified that the performance criteria for the award were met as of February 23, 2026. Each PRSU converts into one share of Class A common stock, and the shares are scheduled to be delivered to Dudum on or about March 15, 2026. Following this acquisition, he directly holds 1,672,734 Class A shares, alongside additional indirect holdings through various family and estate planning trusts.
Hims & Hers Health, Inc. presents its Annual Report describing a fast‑growing, consumer‑focused telehealth and wellness platform built around subscription treatments for chronic conditions such as sexual health, hair loss, hormone health, weight loss, dermatology, and mental health. The company combines licensed Affiliated Medical Groups, wholly owned pharmacies, a 503B outsourcing facility, peptide manufacturing, and a new laboratory testing business to deliver personalized, mostly cash‑pay care in the U.S., U.K., EU, and Canada.
The report highlights growth initiatives including new menopause and testosterone offerings, comprehensive lab testing launched in 2025, and a definitive agreement to acquire Australia‑based Eucalyptus to expand into Australia and Japan. As of February 20, 2026, 219,561,143 Class A and 8,377,623 Class V shares were outstanding. Extensive sections outline a complex regulatory environment, compounded‑drug scrutiny, data‑privacy obligations, and detailed risk factors around competition, compliance, supply chain, and international expansion.
Hims & Hers Health reported another year of rapid growth in 2025. Full-year revenue reached $2.35 billion, up 59%, with subscribers ending at 2.5 million, a 13% increase. Net income was broadly stable at $128.4 million, while Adjusted EBITDA jumped to $318.0 million from $176.9 million, showing stronger underlying profitability.
In the fourth quarter, revenue was $617.8 million, up 28% year over year. Net income declined to $20.6 million, but Adjusted EBITDA improved to $66.3 million. Gross margin compressed to 74% for 2025 from 79%, reflecting mix shifts toward new offerings and international markets.
Operating cash flow rose to $300.0 million in 2025, but Free Cash Flow fell to $57.4 million as the company stepped up capital spending on pharmacies, technology, and infrastructure. For 2026, it guides revenue to $2.7–$2.9 billion and Adjusted EBITDA to $300–$375 million, indicating continued growth while funding expansion.
Hims & Hers Health, Inc. agreed to acquire Australia-based digital health company Eucalyptus for an enterprise value of up to $1,150,000,000, subject to customary adjustments. About $240,000,000 is payable in cash at closing, with additional deferred and earnout payments extending up to early 2029.
The structure relies heavily on deferred consideration of approximately $710,000,000 and potential earnouts of up to approximately $200,000,000, some of which Hims & Hers can settle in Class A common stock at its election. The deal is expected to close around the middle of fiscal year 2026, expanding Hims & Hers’ presence in Australia, Japan, the UK, Germany and Canada.